[go: up one dir, main page]

ATE371737T1 - Proteaseresistente flint-analoge - Google Patents

Proteaseresistente flint-analoge

Info

Publication number
ATE371737T1
ATE371737T1 AT00916264T AT00916264T ATE371737T1 AT E371737 T1 ATE371737 T1 AT E371737T1 AT 00916264 T AT00916264 T AT 00916264T AT 00916264 T AT00916264 T AT 00916264T AT E371737 T1 ATE371737 T1 AT E371737T1
Authority
AT
Austria
Prior art keywords
proteas
analogue
flint
resistant
resistant flint
Prior art date
Application number
AT00916264T
Other languages
English (en)
Inventor
Radmila Micanovic
Radhakrishnan Rathnachalam
Derrick Witcher
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE371737T1 publication Critical patent/ATE371737T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
AT00916264T 1999-03-30 2000-03-20 Proteaseresistente flint-analoge ATE371737T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12683999P 1999-03-30 1999-03-30
US14007399P 1999-06-21 1999-06-21
US14707199P 1999-08-04 1999-08-04
US16052499P 1999-10-20 1999-10-20
US16066999P 1999-10-21 1999-10-21
US17274499P 1999-12-20 1999-12-20
US17818400P 2000-01-26 2000-01-26

Publications (1)

Publication Number Publication Date
ATE371737T1 true ATE371737T1 (de) 2007-09-15

Family

ID=27568834

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00916264T ATE371737T1 (de) 1999-03-30 2000-03-20 Proteaseresistente flint-analoge

Country Status (8)

Country Link
EP (1) EP1165781B1 (de)
JP (1) JP4590504B2 (de)
AT (1) ATE371737T1 (de)
AU (1) AU3739500A (de)
CA (1) CA2368767C (de)
DE (1) DE60036199T2 (de)
ES (1) ES2291197T3 (de)
WO (1) WO2000058466A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
DE69837996T2 (de) 1997-01-14 2008-02-28 Human Genome Sciences, Inc. Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
AU762959B2 (en) 1997-09-18 2003-07-10 Genentech Inc. DcR3 polypeptide, A TNFR homolog
JP2002539828A (ja) * 1999-03-30 2002-11-26 イーライ・リリー・アンド・カンパニー Ｆｌｉｎｔポリペプチドアナログ
WO2001028582A2 (en) * 1999-10-20 2001-04-26 Eli Lilly And Company Therapeutic applications of flint polypeptides
AU2002246967A1 (en) * 2001-02-01 2002-08-12 Eli Lilly And Company Glycoforms a fas ligand inhibitory protein analog
US20040176279A1 (en) * 2001-02-01 2004-09-09 Nigel Jenkins Flint glycoforms
EP1447093A1 (de) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition des CD95 Ligand/Rezeptorsystems zur Behandlung neurologischer Störungen und Verletzungen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837996T2 (de) * 1997-01-14 2008-02-28 Human Genome Sciences, Inc. Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
AU762959B2 (en) * 1997-09-18 2003-07-10 Genentech Inc. DcR3 polypeptide, A TNFR homolog
TR200002824T2 (tr) * 1998-03-30 2000-12-21 Eli Lilly And Company TNF reseptörü üst-ailesinin bir unsuru olan gelişmiş FLINT (mFLINT) polipeptitlerin veya OPG3'ün tedavi amaçlı uygulamaları.

Also Published As

Publication number Publication date
CA2368767C (en) 2008-12-30
EP1165781B1 (de) 2007-08-29
EP1165781A2 (de) 2002-01-02
DE60036199T2 (de) 2008-05-21
WO2000058466A2 (en) 2000-10-05
WO2000058466A3 (en) 2001-01-11
AU3739500A (en) 2000-10-16
JP2002539829A (ja) 2002-11-26
JP4590504B2 (ja) 2010-12-01
ES2291197T3 (es) 2008-03-01
CA2368767A1 (en) 2000-10-05
DE60036199D1 (de) 2007-10-11

Similar Documents

Publication Publication Date Title
DE60006100D1 (de) Lang wirkende insulinotrope peptide
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
BR0108173A (pt) Composições farmacêuticas de toxina de botulina
SE0001899D0 (sv) New compounds
DE60120648D1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
IL138665A0 (en) Peptide factor
NZ284846A (en) 1-substituted-pyrazolo[3,4-b]pyridin-5-carboxylic acid derivatives, preparation, use, intermediates and pharmaceutical compositions thereof
BR0014652A (pt) Fabricação de conjugados de agente terapêutico-poliglutamato
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
HUP0301349A2 (hu) IL-11-tartalmú készítmények
ATE431149T1 (de) Analoge der barbitursäure als therapeutische wirkstoffe
YU68702A (sh) Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka
IT1299583B1 (it) Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
BG106155A (en) Novel derivatives and analogues of galanthamin
ATE371737T1 (de) Proteaseresistente flint-analoge
HUP0202729A2 (hu) Ösztramusztin-foszfátot és aminosavakat tartalmazó, parenteralis felhasználásra szolgáló készítmények
SE0001916D0 (sv) Novel formulation
HUP0300787A2 (hu) Új interferon a sclerosis multiplex kezelésére
IL151647A0 (en) Novel lhrh-antagonists, production and use thereof as medicament
BR0011845A (pt) Complexo farmacêutico
AR023192A1 (es) Analogos de las flint resistentes a proteasas
YU24603A (sh) Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin
HUP0302027A2 (hu) Optikailag aktív 2-aminotetralin-származékok, eljárás ezek előállítására, és ezeket tartalmazó gyógyászati készítmények terápiás alkalmazása
EP1730174A4 (de) Peptidträger für die verabreichung von arzneimitteln
PT1150716E (pt) Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties